ClinicalTrials.gg
WithdrawnNCT03492710Updated Jul 7, 2020

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

A Phase 3 interventional study of Immunoglobulin in Primary Immune Deficiency Disorder, sponsored by Green Cross Corporation. Withdrawn. Open to participants aged 24 Months to 203 Months. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Green Cross Corporation · Phase 3, Interventional, and Treatment

Why this study was withdrawn
A change in sponsor's developmental strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
24 Months to 203 Months
Sex
All
01

Study summary

To assess the safety, efficacy, and pharmacokinetics of IGIV-SN in pediatric subjects with primary immunodeficiency humoral diseases (PHID)

02

Conditions studied

  • Primary Immune Deficiency Disorder
03

In context

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Months to 203 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric subjects with a confirmed clinical diagnosis of a Primary Humoral Immunodeficiency Disease as defined by IUIS (International Union of Immunological Societies) and require treatment with IGIV. Documented agammaglobulinemia or hypogammaglobulinemia
  • Subject is willing to comply with all requirements of protocol
  • Authorization to access personal health information

Exclusion criteria

Exclusion Criteria:

  • Subject has secondary immunodeficiency
  • Subject has a history of repeated reactions or to IGIV or other injectable forms of IgG
  • Subject has significant protein loss from enteropathy, nephrotic syndrome or lymphangiectasia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    IGIV-SN

    Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)

    Biological: Immunoglobulin

Interventions

  • BiologicalImmunoglobulin

    Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more

    Also known as: IGIV-SN

06

What researchers measure

Primary outcomes

  1. Efficacy: Incidence of Acute SBIs (Serious Bacterial Infections)

    The incidence of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess

    Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)

  2. Safety: Overall Incidence of AEs that occur during 72 hours of following an infusion of test drug

    The overall incidence of adverse events (AEs) that occur during or within 1 hours, 24 hours, and 72 hours following an infusion of test product, regardless of whether or not the AE is determined to be product related

    Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)

Secondary outcomes

  1. Efficacy: Incidence of Infections other than acute serious bacterial infections

    Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)

  2. Safety: The frequency of all AEs that occuring during the study

    (regardless of the casual relationship)

    Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)

Other outcomes

  1. PK Endpoint (1)

    Plasma Concentration-Time Curve (PK Parameters of Total IgG)

    Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)

  2. PK Endpoint (2)

    Area Under the Curve (PK Parameters of Total IgG)

    Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Apr 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2018
First posted
Apr 10, 2018
StartActual
Apr 30, 2019
Primary completionActual
Apr 30, 2019
CompletionActual
Apr 30, 2019
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03492710
Responsible party
Sponsor
First posted
Apr 10, 2018
Start date
Apr 30, 2019
Primary completion
Apr 30, 2019
Completion
Apr 30, 2019
Last update
Jul 7, 2020

Study contacts

Chaim Roifman
principal investigator · The Hospital for Sick Children

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion